troglitazone has been researched along with Lipodystrophy, Familial Partial in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Lipodystrophy, Familial Partial: Inherited conditions characterized by the partial loss of ADIPOSE TISSUE, either confined to the extremities with normal or increased fat deposits on the face, neck and trunk (type 1), or confined to the loss of SUBCUTANEOUS FAT from the limbs and trunk (type 2). Type 3 is associated with mutation in the gene encoding PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maraldi, NM | 1 |
| Capanni, C | 1 |
| Mattioli, E | 1 |
| Columbaro, M | 1 |
| Squarzoni, S | 1 |
| Parnaik, WK | 1 |
| Wehnert, M | 1 |
| Lattanzi, G | 1 |
1 other study available for troglitazone and Lipodystrophy, Familial Partial
| Article | Year |
|---|---|
A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome.
Topics: Adipocytes; Body Fat Distribution; Cell Differentiation; Chromans; Humans; Insulin Resistance; Lamin | 2007 |